Semisynthesis and pharmacological activities of Tetrac analogs: Angiogenesis modulators

https://doi.org/10.1016/j.bmcl.2009.04.094Get rights and content

Abstract

Novel Tetrac analogs were synthesized and then tested. Anti-angiogenesis efficacy was carried out using the Chick Chorioallantoic Membrane (CAM) model and the mouse matrigel model for angiogenesis. Pharmacological activities showed Tetrac can accommodate numerous modifications and maintain anti-angiogenesis activity.

Graphical abstract

Pharmacological activities of powerful Tetrac analogs were found.

  1. Download : Download full-size image

Section snippets

Acknowledgments

Thanks to Azopharma’s contribution in regards to the synthesis and analytical characterization of the EBH-Tetrac-OTiPS compound, the Rensselaer Polytechnic Institute (NMR analyses), to the University at Albany Proteomics Facility, the Center for Functional Genomics for the MS analysis, to Dr. Huazhong HE, PRI for reviewing this article and to Dr. Jay Jayaraman, PRI for his help and constant support. We appreciate the partial funding of this work by the Charitable Leadership Foundation and the

References and notes (15)

  • V. Cody et al.

    Steroids

    (2007)
  • S.A. Mousa et al.

    Angiogenesis

    (2008)
  • J.J. Bergh et al.

    Endocrinolgy

    (2005)
  • S.R. Hill et al.

    J. Clin. Invest.

    (1960)
  • J.-P. Xiong et al.

    Science

    (2001)
  • J.-P. Xiong et al.

    Science

    (2002)
  • J.H. Wilkinson

    Biochem. J.

    (1956)
There are more references available in the full text version of this article.

Cited by (18)

  • Synthesis and characterization of <sup>64</sup>Cu- and Cy5.5-labeled tetraiodothyroacetic acid derivatives for tumor angiogenesis imaging

    2020, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    Tetrac has been modified at the hydroxy and/or carboxylic acid end(s) without losing its antiangiogenic activity.12,13 Most tetrac derivatives showed antiangiogenic activity similar or superior to that of tetrac in the chick chorioallantoic membrane (CAM) assay and mouse Matrigel model.12 In another study, tetrac was substituted with a guanidine, urea, or aminopropyl group at the hydroxy position, and all three of those derivatives exhibited antiangiogenic activity similar to that of tetrac in CAM assays.13

  • Pro- and anti-angiogenic agents

    2012, Journal des Maladies Vasculaires
    Citation Excerpt :

    Also, this potential new drug has been revealed to suppress the proliferation of cancer cell lines that already have reached the resistant state to numerous anti-cancer drugs such as doxorubicin in vivo [30]. The discovery that tetrac induced the blockade of neo-angiogenesis by interacting with the same cell-surface integrin as T4 has boosted the development of a new formulation for tetrac with enhanced activity [31]. The nanoparticulate tetrac (Fig. 1) has revealed its potent activity against the medullary carcinoma of the thyroid and against human renal carcinoma [32–35].

  • Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts

    2012, Lung Cancer
    Citation Excerpt :

    Amino-functionalized PLGA-NPs were obtained by conjugating PLGA-NPs with ethylenediamine, using carbodiimide chemistry. Finally, amino-functionalized PLGA-NPs were reacted with tetrac intermediate [30] to obtain the final product, tetrac-conjugated PLGA-NPs. The custom-made intermediate of tetrac was conjugated to epibromohydrin through the phenolic –OH group present on the outer ring of tetrac.

  • Thyroid hormone as a regulator of tumor induced angiogenesis

    2011, Cancer Letters
    Citation Excerpt :

    Tetrac enhanced cellular response to doxorubicin, etoposide, cisplatin, and trichostatin A in resistant tumor cell lines derived from neuroblastoma, osteosarcoma, and breast cancer [95]. Recently, new tetrac and TH analogs have been synthesized and shown to have increased anti-angiogenic effect both in CAM and mouse–matrigel models [97,98]. In conclusion, TH, and in particular T4, are now seen as non-classic mediators of tumor angiogenesis and proliferation.

View all citing articles on Scopus
View full text